Ethinylestradiol/gestodene triphasic

Drug Profile

Ethinylestradiol/gestodene triphasic

Alternative Names: Gestodene/ethinylestadiol triphasic; Milvane; Phaeva; Tri Femoden; Tri Gynera; Tri-Minulet; Triadene; Trigynera; Trigynovin; Triminulet; Triminulet 28; Triodeen; Trioden ED; Triodena; Triodene

Latest Information Update: 09 Feb 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Akromed; Bayer HealthCare Pharmaceuticals; Wyeth
  • Class Alkylated estrogenic steroids; Norpregnatrienes; Norpregnenes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 09 Feb 2015 Launched for Contraception/Pregnancy (Prevention) in Denmark, Poland and Hungary (PO) prior to February 2015
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top